On a Tuesday morning in April 2026, a 63-year-old Norwegian man walked out of Oslo University Hospital without taking his daily HIV medication — a routine he had followed for 14 years — because tests showed no trace of the virus in his blood, gut, or spinal cord.
This moment marked the latest in a string of rare cases where a stem cell transplant, performed to treat a life-threatening blood cancer, also eradicated HIV. The man, known only as the “patient of Oslo,” had been HIV-positive since 2006 and diagnosed with myelodysplastic syndrome in 2017. By 2020, his cancer had relapsed, leaving a stem cell transplant as his only option. His older brother volunteered as a donor, and though neither knew it at the time, the brother carried a rare genetic mutation called CCR5-delta 32 — present in roughly 1% of people of European descent — that blocks HIV from entering immune cells.
The transplant, conducted in 2020, replaced the patient’s blood and immune system with his brother’s stem cells. Unbeknownst to the medical team until after the procedure, this effectively gave the patient a new immune system inherently resistant to HIV. Two years later, doctors stopped his antiretroviral therapy. Since then, ultrasensitive tests have found no detectable virus, a state researchers now describe as sustained remission, if not a cure.
The case, detailed in a study published in Nature Microbiology on April 13, 2026, adds the Oslo patient to a growing but still tiny group of individuals — estimated at around a dozen — in whom HIV has disappeared following a stem cell transplant for cancer. Like the Berlin and London patients before him, the Oslo case hinges on the same biological mechanism: replacing HIV-susceptible immune cells with those lacking functional CCR5 receptors.
What distinguishes this case is the role of familial luck. Doctors first searched registries for a donor with the CCR5 mutation but found no match. Only then did they test the patient’s older brother, who, despite not being sought for his genetics, turned out to be a perfect HLA match and a carrier of the protective variant. As the patient’s lead physician, Anders Eivind Myhre, told AFP, the brother’s dual compatibility felt “like winning the lottery twice.”
The procedure itself remains extraordinarily risky. Stem cell transplantation requires chemotherapy or radiation to destroy the patient’s existing bone marrow, leaving them vulnerable to infection, organ damage, and graft-versus-host disease. For the vast majority of the 39 million people living with HIV globally, the dangers far outweigh the potential benefit, especially when antiretroviral therapy can suppress the virus to undetectable levels with minimal side effects.
Still, these rare cases offer scientists a window into HIV’s persistence. Each successful transplant reinforces the idea that eliminating CCR5-expressing cells can prevent viral rebound, even after stopping treatment. Researchers hope that studying the Oslo patient’s immune reconstitution — particularly how his body maintains immunity without HIV susceptibility — may inform future gene-editing or immunotherapy strategies aimed at mimicking this effect without transplant.
As of 2026, no alternative approach has replicated this outcome at scale. Gene therapies targeting CCR5 remain experimental, and efforts to deliver HIV-resistant stem cells through less toxic means are still in early trials. For now, the Oslo patient’s recovery stands as a biological anomaly — a convergence of medical necessity, genetic rarity, and familial chance — that underscores both the limits and the ingenuity of modern medicine.
Despite the excitement, clinicians urge caution. The Oslo case, like those before it, does not signal a near-term cure for HIV. Stem cell transplants remain reserved for patients with fatal blood cancers who have no other options. The procedure’s mortality rate, while reduced in specialized centers, still exceeds 10% in many settings.
Yet the psychological impact on patients and clinicians is real. For the Oslo man, described by his doctors as “in excellent health and full of energy,” the dual recovery from cancer and HIV has restored a sense of normalcy after years of dual surveillance. His story, while not replicable, reinforces a fundamental truth in virology: under the right conditions, even a virus once thought permanent can be displaced.
How rare is the CCR5-delta 32 mutation that made this cure possible?
The CCR5-delta 32 mutation, which prevents HIV from entering immune cells, occurs in about 1% of people of European descent and is much rarer in other populations. Having two copies — as the donor did — is required for near-complete resistance to common HIV strains.
Why can’t this treatment be used for most people living with HIV?
Stem cell transplants carry significant risks, including infection and graft-versus-host disease, and are only justified when treating life-threatening cancers. For most people with HIV, antiretroviral therapy effectively controls the virus with far lower risk.